Skip to main content


Preconditioning of murine mesenchymal stem cells synergistically enhanced immunomodulation and osteogenesis



Mesenchymal stem cells (MSCs) are capable of immunomodulation and tissue regeneration, highlighting their potential translational application for treating inflammatory bone disorders. MSC-mediated immunomodulation is regulated by proinflammatory cytokines and pathogen-associated molecular patterns such as lipopolysaccharide (LPS). Previous studies showed that MSCs exposed to interferon gamma (IFN-γ) and the proinflammatory cytokine tumor necrosis factor alpha (TNF-α) synergistically suppressed T-cell activation.


In the current study, we developed a novel preconditioning strategy for MSCs using LPS plus TNF-α to optimize the immunomodulating ability of MSCs on macrophage polarization.


Preconditioned MSCs enhanced anti-inflammatory M2 macrophage marker expression (Arginase 1 and CD206) and decreased inflammatory M1 macrophage marker (TNF-α/IL-1Ra) expression using an in-vitro coculture model. Immunomodulation of MSCs on macrophages was significantly increased compared to the combination of IFN-γ plus TNF-α or single treatment controls. Increased osteogenic differentiation including alkaline phosphate activity and matrix mineralization was only observed in the LPS plus TNF-α preconditioned MSCs. Mechanistic studies showed that increased prostaglandin E2 (PGE2) production was associated with enhanced Arginase 1 expression. Selective cyclooxygenase-2 inhibition by Celecoxib decreased PGE2 production and Arginase 1 expression in cocultured macrophages.


The novel preconditioned MSCs have increased immunomodulation and bone regeneration potential and could be applied to the treatment of inflammatory bone disorders including periprosthetic osteolysis, fracture healing/nonunions, and osteonecrosis.


Mesenchymal stem cells (MSCs) have been specifically defined by the International Society for Cellular Therapy [1]. Potential translational applications of MSCs are highlighted by their properties for immunomodulation and tissue regeneration including those that relate to bone. MSC-based cell therapies have been applied to clinical trials of inflammatory disorders including graft-versus-host disease, diabetes, myocardial infarction, and osteoarthritis [2].

MSC-based therapies may have great potential for treatment of inflammatory bone disorders. Inflammation has a crucial but distinct role in bone healing and the remodeling process [3]. For example, acute inflammation is necessary for successful fracture healing and bone regeneration [4]. Depletion of macrophages greatly impaired bone healing in a murine bone injury model [5]. However, unresolved inflammation with excessive proinflammatory cytokines and chemokines mainly secreted by macrophages leads to impaired bone formation and increased bone destruction (osteolysis) [6]. In addition, sequential exposure of MSC-lineage cells to inflammatory M1 macrophages (tumor necrosis factor alpha (TNF-α)/interleukin-1 receptor antagonist (IL-1Ra)high) and anti-inflammatory M2 macrophages (Arginase 1 (Arg1)high and CD206high) further enhanced osteogenic differentiation in vitro [7]. Therefore, stimulation of MSCs by inflammatory signals and sequential modulation of macrophage polarization status is crucial for optimizing bone formation. Studies using transgenic animals demonstrated that NF-κB signaling (a major downstream signaling of inflammatory stimulation) negatively regulated bone formation [8]; however, the effects of inflammatory ligand stimulation on osteogenic differentiation of MSCs depended on the dose, type, and timing of the stimulation [9]. Exposure of MSCs to a lower dose (0.1–5 ng/ml) of TNF-α inhibited, while a higher dose (50 ng/ml) increased, osteogenic differentiation in vitro [10, 11]. The induction of osteogenesis mediated by inflammatory stimulation, including TNF-α and lipopolysaccharide (LPS), was only observed with early treatment of MSCs [12,13,14,15,16].

Previous studies have shown that in addition to osteogenic potential, MSC-mediated immunomodulation could be regulated by proinflammatory cytokines [17, 18] or bacterial endotoxin [19]. MSCs exposed to LPS attenuated the response to sepsis by upregulating IL-10 secretion in macrophages by secretion of prostaglandin E2 (PGE2) [19]. MSCs exposed to the combination of interferon gamma (IFN-γ) and proinflammatory cytokines such as TNF-α, but not by either IFN-γ or TNF-α alone, reduced T-lymphocyte-mediated and macrophage-mediated immune responses [17, 18]. These results suggest that stimulation by multiple inflammatory factors is required to enhance MSC-mediated immunomodulation in a synergistic manner. However, the application of IFN-γ plus TNF-α preconditioned MSCs in bone disorders could be limited by the potential detrimental effect of IFN-γ plus TNF-α on MSC self-renewal and lineage differentiation [20].

In the current study, we show that preconditioning of MSCs with TNF-α and LPS enhances the immunomodulatory properties of MSCs on M1 to M2 macrophage polarization and simultaneously increases the osteogenic differentiation of MSCs. The strategic use of preconditioned MSCs could be applied to inflammatory bone disorders and bone tissue engineering, as well as chronic inflammatory disorders with excessive macrophage-mediated proinflammatory activation.


Isolation of murine mesenchymal stem cells and macrophages

The methods of isolating murine bone marrow-derived MSCs and macrophages have been described previously [21, 22]. Stanford’s Administrative Panel on Laboratory Animal Care (APLAC) approved this isolation protocol (APLAC 17566). In brief, bone marrow was collected from the femurs and tibias of C57BL/6 J male mice 8–10 weeks old. Institutional guidelines for the care and use of laboratory animals were observed in all aspects of this project. For MSC isolation, the cells were carefully suspended and passed through a 70-μm strainer, spun down, and resuspended in α-MEM supplied with 10% MSC certified fetal bovine serum (FBS; Invitrogen) and antibiotic antimycotic solution (100 units of penicillin, 100 μg of streptomycin, and 0.25 μg of Amphotericin B per ml; Hyclone, Thermo Scientific). The fresh medium was replaced on the next day to remove the unattached cells (passage 1). The immunophenotype of isolated MSCs (Sca1+/CD105+/CD44+/CD45/CD34/CD11b; Additional file 1: Figure S1) was characterized by LSR II flow cytometer (BD Bioscience) at passage 4. For macrophage isolation, the bone marrow cells were washed three times with culture medium (RPMI 1640 medium supplemented with 10% heat-inactivated FBS, and the antibiotic/antimycotic solution), resuspended in the culture medium containing 30% of L929 cells conditioned medium and 10 ng/ml mouse macrophage colony stimulation factor (M-CSF), and replated in T-175 culture flasks at a concentration of 4 × 107 cells per flask. Cells were allowed to expand for 5–7 days, with a medium change on the second day to remove nonadherent cells. Macrophages were confirmed by double-positive staining of cells (> 98.5%) using the surface markers F4/80 and CD11b for flow cytometric analysis after day 7.

Preconditioning of mesenchymal stem cells and coculture with macrophages

A summary of the experimental strategy is illustrated in Fig. 1a. At day 0, MSCs (1 × 104 cells) were seeded in 24-well transwell plates (0.3 μm; Corning) in the bottom chamber with MSC growth medium. After cell attachment (day 1), the cells were treated with 20 ng/ml TNF-α and 1–20 μg/ml LPS for 3 days as indicated in the figure legend. The cells treated with 20 ng/ml TNF-α or 20 μg/ml LPS alone or the combination of 20 ng/ml IFN-γ and 20 ng/ml TNF-α [17] were used as controls. The dose of TNF-α and IFN-γ was determined according to previous studies of immunomodulation by MSCs [17, 18]. The dose of LPS was titrated (Additional file 1: Figure S1) in the range of previous studies on LPS-treated MSCs [10, 11]. Primary macrophages (2 × 103 cells) were seeded to the insert of a separate transwell plate and polarized into the M1 phenotype by exposure to 20 ng/ml IFN-γ (day 3) for 24 hours. At day 4, MSCs and macrophages were washed three times with PBS and the inserts with the M1 macrophages were moved to the plates containing the preconditioned MSCs at the bottom of the well. This coculture was carried out in MSC growth medium for 24 hours. Celecoxib (25 μM) was used to block the cyclooxygenase (COX) signaling in selected groups for further mechanistic experiments. The medium was supplemented with 30 μg/ml polymyxin B1 to inactivate any trace amounts of LPS which could potentially impact the culture system.

Fig. 1

Immunomodulation of preconditioned MSCs on murine macrophages. a Preconditioning and coculture model. Murine MSCs were preconditioned with IFN-γ plus TNF-α (I + T, 20 ng/ml each), LPS (20 μg/ml) plus TNF-α (L + T), LPS alone (L), or TNF-α alone (T) for 3 days, and cocultured with M1 macrophages for 24 hours. b M2 (Arg1 and CD206) and M1 (TNF-α/IL-1Ra) macrophage marker expression in macrophages measured by quantitative PCR. Data presented as fold-change compared to macrophages cocultured with unstimulated control MSCs. c, d Expression of M2 macrophage markers (Arg1 and CD206) at protein level examined by flow cytometry. ***p < 0.005. Arg1 Arginase 1, IFN interferon, IL1Ra interleukin-1 receptor antagonist, MSC mesenchymal stem cell, TNF tumor necrosis factor

Quantitative PCR

Cellular RNA from macrophages in the coculture system was extracted using the RNeasy RNA purification kit (Qiagen, Valencia, CA, USA). RNA was reverse transcribed into complementary DNA (cDNA) using a high-capacity cDNA archive kit (Applied Biosystems, Foster City, CA, USA). Probes for 18 s rRNA, TNF-α, IL-1Ra, Arg1, and CD206 were purchased from Applied Biosystems. Reverse-transcriptase polymerase chain reaction (RT-PCR) was performed in an ABI 7900HT Sequencing Detection System (Applied Biosystems), using 18 s rRNA as the internal control. The –ΔΔCt relative quantization method was used to evaluate the gene expression level.

Flow cytometry analysis of macrophage polarization markers

MSCs were seeded in 10-cm cell culture dishes and preconditioned or left untreated as described earlier. The conditioned media were collected 24 hours after the cells were washed and replaced with fresh medium. The conditioned media were diluted with macrophage growth medium at 1:1 ratio and used to treat IFN-γ-polarized macrophages for 24 hours. The cells were harvested into single cell suspension and stained with anti-CD206 antibody conjugated with PE (eBioscience), and processed by flow cytometry fixation and permeabilization buffer kit (R&D) for the following intracellular staining of Arg1 (FITC). Stained macrophages were analyzed by LSRII.

Prostaglandin E2 quantification

Cellular supernatant from the coculture system was collected at the indicated time points. Concentration of PGE2 in the supernatant was measured by the PGE2 parameter assay kit (R&D system). The manufacturer’s protocol was followed carefully.

Osteogenesis assay

After preconditioning (see Preconditioning of mesenchymal stem cells and coculture with macrophages for details), the MSCs were switched into osteogenic medium (α-MEM supplemented with 10% FBS, 100 nM dexamethasone, 10 mM β-glycerol phosphate, and 50 μM ascorbate-2-phosphate) supplemented with 30 μg/ml polymyxin B1 to inactivate the trace LPS in the system. Cell lysate at week 2 was used for the alkaline phosphatase (ALP) activity assay (QuantiChrome™ Alkaline phosphatase assay kit, Cat. No. DALP-250; Bioassay Systems, Hayward, CA, USA). Extracellular matrix mineralization by the murine MSCs was identified using Alizarin Red stain at week 3. Celecoxib (25 μM) was used to block the COX2 signaling at indicated time points described in figure legends. The results were photographed, and the staining was eluted by 10% cetylpyridinium chloride and quantified by measuring the absorbance at 562 nm.

Statistical analysis

Nonpaired t tests were performed for data with two groups, and one-way ANOVA with Tukey’s post-hoc test was performed for data with three or more groups. The statistical analysis was conducted using Prism 7 (GraphPad Software, San Diego, CA, USA). Data are reported as mean ± standard error of the mean. The osteogenesis assay was performed with four replicates. Quantitative PCR was performed in triplicate. The experiments have been repeated twice in three or four replicates independently. p < 0.05 was chosen as the threshold of statistical significance.


Preconditioned MSCs modulated macrophages into an anti-inflammatory phenotype

Murine MSCs were preconditioned and cocultured with murine bone marrow-derived macrophages as described in Methods and Fig. 1a. MSCs preconditioned with IFN-γ plus TNF-α were included as a positive control, because this conditioning has been demonstrated previously to enhance the modulation of both innate and adaptive immune responses [17, 18]. Activation of proinflammatory cytokines (TNF-α) also induces the production of anti-inflammatory cytokines (IL-1Ra) as a negative feedback mechanism to avoid overwhelming inflammation. The status of macrophage polarization was thus shown in the ratio of TNF-α/IL-1Ra expression [7, 23]. First, LPS dosage was titrated by treating MSCs with varying dosages of LPS (0.1–20 μg/ml) together with 20 ng/ml TNF-α [17, 18]. We found that preconditioning with 20 μg/ml LPS optimally enhanced the ability of MSCs to induce anti-inflammatory phenotypes in macrophages (Arg1high, CD206high, TNF-α/IL-1Ralow; Additional file 1: Figure S2). Preconditioned MSCs with LPS plus TNF-α synergistically enhanced M2 macrophage marker (Arg1high and CD206high) and decreased M1 macrophage marker (TNF-α/IL-1Ralow) expression in the cocultured M1 macrophages (Fig. 1b). MSCs preconditioned with LPS (20 μg/ml) or TNF-α (20 ng/ml) alone, or with the combination of IFN-γ and TNF-α (20 ng/ml each), induced the anti-inflammatory phenotypes in M1 macrophages at lower levels. M2 marker expression in macrophages (Arg1 and CD206) at the protein level was further confirmed using the conditioned medium from MSCs (Fig. 1c, d). The Arg1high population was increased from 32.5 to 67.9%, and the CD206+ population was increased from 47.7 to 55.7%, respectively. Together, the combination of LPS and TNF-α preconditioning further enhanced the immunomodulation by MSCs compared to other conditions.

Preconditioned MSCs with LPS plus TNF-α enhanced osteogenic differentiation

The osteogenic ability of MSCs using various preconditioning protocols was then examined. MSCs preconditioned with LPS plus TNF-α significantly enhanced ALP activity (p < 0.005) and bone mineralization (p < 0.01); however, MSCs preconditioned with LPS increased bone mineralization (p < 0.05) but had no significant effect on ALP activity (Fig. 2a, b). MSCs preconditioned with TNF-α alone or with IFN-γ plus TNF-α did not affect the ALP activity and mineralization.

Fig. 2

Increased osteogenic differentiation of MSCs preconditioned with LPS plus TNF-α. MSCs were preconditioned with IFN-γ plus TNF-α (I + T, 20 ng/ml each), LPS (20 μg/ml) plus TNF-α (L + T), LPS alone (L), or TNF-α alone (T) for 3 days in growth media, and replaced by osteogenic media for 3 weeks. The osteogenic differentiation ability was examined by ALP activity at week 2 (a) and bone mineralization (Alizarin Red staining) at week 3 (b). *p < 0.05, **p < 0.01, ***p < 0.005. ALP alkaline phosphatase, MSC mesenchymal stem cell

Increased prostaglandin E2 production in preconditioned MSCs is associated with enhanced Arginase 1 expression in macrophages

Inflammatory stimulation by TNF-α induces PGE2 production through the NF-κB/COX2-dependent pathway [24]. PGE2 secretion by MSCs is associated with the inhibition of inflammatory response [19, 25, 26] and the induction of osteogenic differentiation [27, 28]. We found that PGE2 production was significantly increased in the preconditioned MSCs including the groups treated with IFN-γ plus TNF-α, LPS plus TNF-α, and TNF-α alone, which could be reversed by a selective COX2 inhibitor (25 μM Celecoxib) (Fig. 3). MSCs preconditioned with LPS did not increase PGE2 production (p = 0.10). In the coculture model, inhibition of COX2 signaling by Celecoxib clearly suppressed Arg1 expression in macrophages cocultured with preconditioned MSCs (Fig. 4). However, the preconditioned MSC-mediated changes in CD206 and TNF-α/IL-1Ra were not affected by inhibition of COX2 signaling.

Fig. 3

Induction of PGE2 secretion in preconditioned MSCs through the COX-2-dependent pathway. MSCs were preconditioned with IFN-γ plus TNF-α (I + T, 20 ng/ml each), LPS (20 μg/ml) plus TNF-α (L + T), LPS alone (L), or TNF-α alone (T) for 3 days, and replaced with fresh media with or without Celecoxib (25 μM) to modulate COX2 signaling. After 24 hours of incubation, the supernatants were collected, and PGE2 production was quantified by ELISA. *p < 0.05, **p < 0.01. COX2 cyclooxygenase-2, MSC mesenchymal stem cell, PGE2 prostaglandin E2

Fig. 4

Immunomodulation ability of preconditioned MSCs mediated by PGE2 secretion. MSC/macrophage cocultured experiments were performed as described in Fig. 1a. Media were supplied with or without 25 μM Celecoxib to modulate COX2 signaling. M2 (Arg1 and CD206) and M1 (TNF-α/IL-1Ra) macrophage marker expression in macrophages was measured by quantitative PCR. Data presented as fold-change compared to macrophages cocultured with unstimulated control MSCs. *p < 0.05, **p < 0.01, ***p < 0.005. Arg1 Arginase 1, IL1Ra interleukin-1 receptor antagonist, MSC mesenchymal stem cell, TNF tumor necrosis factor

Blocking the COX2/PGE2 pathway does not interfere with enhanced osteogenesis in preconditioned MSCs

We further examined the effects of increased PGE2 production on the osteogenic differentiation of preconditioned MSCs. Inhibition of the COX2/PGE2 pathway by Celecoxib during the first week of osteogenesis significantly enhanced ALP activity and mineralization in both the untreated and preconditioned (LPS plus TNF-α) MSCs (Fig. 5a, b). To further clarify how the COX2/PGE2 pathway regulated the osteogenic differentiation of MSCs in vitro, the MSCs were treated with Celecoxib at week 1, week 2, week 3, or continuously during the osteogenesis (weeks 1–3). Temporal inhibition of COX2 signaling enhanced bone mineralization in MSCs regardless of the treatment time points, while continuous treatment showed no significant effects compared to the untreated controls (Additional file 1: Figure S3).

Fig. 5

Inhibition of COX-2/PGE2 pathway increased osteogenesis in untreated or preconditioned MSCs. MSCs were preconditioned with LPS plus TNF-α in growth media, and replaced with osteogenic media for 3 weeks. Media were supplied with or without 25 μM Celecoxib during the first week of osteogenesis. Osteogenic differentiation ability examined by ALP activity at week 2 (a) and bone mineralization (Alizarin Red staining) at week 3 (b). *p < 0.05, **p < 0.01. ALP alkaline phosphatase, COX2 cyclooxygenase-2, MSC mesenchymal stem cell


Immunomodulation and tissue regeneration are fundamental mechanisms in MSC-based cellular therapy. These biological features are closely regulated in response to local environmental cues including the oxygen level, presence of growth factors and inflammatory cytokines, and other factors. Changes in the microenvironment during disease progression could provoke protective “pre-homeostatic” mechanisms in MSCs and further enhance their therapeutic efficiency [29,30,31,32]. Indeed, our current findings show that MSCs preconditioned with LPS plus TNF-α, macrophage-associated inflammatory mediators, synergistically enhanced M2 macrophage polarization and osteogenic differentiation.

Previous studies of MSC preconditioning have mainly focused on studying the effects of a single inflammatory mediator on MSCs [19, 29,30,31,32,33]. These approaches have clarified valuable information regarding the biological features of MSCs. However, as the complex tissue microenvironment contains multiple inflammatory factors, we speculated that it might be possible to further enhance the beneficial osteogenic and immunomodulatory properties of MSCs by exposing the cells to multiple inflammatory mediators. IFN-γ is mainly produced by activated Th1 lymphocytes and is a crucial regulator of both innate and adaptive immune response [34]. Ren et al. [17] demonstrated that MSC-mediated suppression of T-lymphocyte activation required the presence of IFN-γ and one of the proinflammatory cytokines TNF-α, IL-1α, or IL-1β. LPS is a potent ligand for macrophages that activates the proinflammatory response including TNF-α production via TLR4 signaling. TNF-α is a strong proinflammatory cytokine, produced in high amounts during inflammatory and immune reaction by various cells including M1 macrophages and Th1 cells. Our preconditioning strategy using high-dose LPS and TNF-α could incite physiological protective mechanisms against an overt inflammatory reaction and enhance the immunomodulatory properties of MSCs [19]. However, the proinflammatory stimulation-induced immunomodulation could also manipulate the infiltrated MSCs into tumor-derived MSCs and enhance tumor progression [35]. Indeed, as both TLR ligands and macrophage-derived TNF-α are likely to be present at the site of injury, they might work synergistically to induce the physiological transition from acute inflammation to tissue regeneration. Previous studies have shown that the application of MSCs preconditioned by a single factor improved tissue repair using in-vivo models [32, 36], demonstrating that ex-vivo conditioning with factors such as LPS/TNF-α can stably increase their therapeutic efficiency. The underlying mechanisms of synergistic effect by LPS plus TNF-α or other proinflammatory cytokines remain unclear.

Crosstalk between MSCs and macrophages including paracrine regulation and direct cell contact is crucial for effective immunomodulation and tissue regeneration [7, 19, 33]. Our current transwell coculture and conditioned medium treatment models demonstrated that paracrine factors secreted by the preconditioned MSCs were effective in modulating macrophage polarization from the inflammatory M1 phenotype toward the anti-inflammatory and tissue-regenerative M2 phenotype. Previous studies have shown that direct PGE2 treatment of macrophages increased M2 markers including Arg1, IL-10, and MMP9, and that this effect was blocked by PGE2 inhibitors [37,38,39]. In the current study, inhibition of the COX2/PGE2 pathway blocked the upregulation of M2-related Arg1 expression in macrophages, which is correlated with tissue repair. However, blocking of the COX2/PGE2 pathway had limited effects on CD206 expression and TNF-α/IL-1Ra ratio, suggesting that other secreted factors are also involved in immunomodulation. A previous proteomic analysis has identified 118 TNF-induced paracrine factors in human adipose-derived MSCs including various cytokines, chemokines, proteinases, and immune modulators such as long pentraxin 3 [40]. Analysis of paracrine factors secreted by the preconditioned MSCs is required to further clarify the underlying mechanisms of immunomodulation. Nemeth et al. [19] have shown that MSCs induced anti-inflammatory cytokine production in macrophages in the coculture system of direct contact or transwell (paracrine regulation only) models. The induction is higher with direct cell-to-cell contact compared to paracrine regulation alone, indicating that both physical contact and paracrine factors are involved in the MSC-mediated immunomodulation. Our study focused on the transwell system to clarify the MSC-mediated paracrine factors including nitric oxide and PGE2. Currently, the molecular candidates involved in the immunomodulation via physical contact between MSCs and macrophages remain unclear. Our data showed that MSC preconditioning alone increased osteogenic differentiation in the absence of macrophages in vitro. Sequential modulation of macrophage polarization status by the preconditioned MSCs could further enhance the osteogenic potential during this crosstalk [7].

MSCs can modulate adaptive and innate immunity by distinct mechanisms. Ren et al. [17] showed that MSC-mediated suppression of T-cell proliferation required iNOS-dependent nitric oxide production. Exposure of LPS plus TNF-α synergistically induced iNOS expression in MSCs (Additional file 1: Figure S4); however, selective inhibition of iNOS activity showed a limited effect on M2 macrophage polarization (data not shown). In addition, mechanistic studies demonstrated that the IFN-γ and TNF-α-induced immunomodulation in human MSCs is mediated by indoleamine 2,3-dioxygenase (IDO) instead of the iNOS pathway [18]. The different potential mechanisms to modulate macrophage polarization between human and mouse MSCs exposed to LPS plus TNF-α remain to be clarified.

The critical roles of COX2 in bone formation and repair have been demonstrated in COX2 knockout transgenic mouse [28, 41, 42], and by rat and rabbit models using nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) [43,44,45]. However, clinical findings regarding the effects of COX-2 inhibitors and other NSAIDs on bone formation remain controversial [46,47,48]. Our data showed that transient inhibition of COX2 in MSCs by the selective COX-2 inhibitor Celecoxib increased osteogenesis, regardless of the treatment time points (Additional file 1: Figure S3). Interestingly, continuous treatment with Celecoxib had no significant effects on osteogenic differentiation. Other in-vitro studies showed that the suppressive effect of Celecoxib on osteogenesis was only observed in the presence of inflammatory environments, such as proinflammatory cytokines or macrophages [49, 50]. Therefore, the increased osteogenesis in MSCs treated with Celecoxib could be limited to our in-vitro model in the absence of other proinflammatory environmental factors.

Preconditioned MSCs could display proinflammatory or anti-inflammatory phenotypes in response to different ligands [51]. Transient exposure (< 1 hour) of MSCs to 10 ng/ml LPS led to proinflammatory “MSC1” phenotypes and increased T-cell activation in the coculture experiment. Comparatively, the “MSC2” phenotype exposed to 1 μg/ml poly I:C was able to suppress T-cell activation, enhance IDO expression, and increase PGE2 production [51]. Our data and other studies show that MSCs exposed to LPS (1–20 μg/ml) induced a protective anti-inflammatory effect on macrophages [19, 52]. The difference in the dose, exposure time, and affected cell types (T lymphocytes or macrophages) could determine the biological roles of LPS-preconditioned MSC.


Our novel preconditioning strategy enhanced both immunomodulation and bone regeneration abilities of MSCs. This approach has great potential in the application of MSC-based therapy for the treatment of inflammatory bone disorders including periprosthetic osteolysis, fracture healing/nonunions, and osteonecrosis.



Alkaline phosphatase


Analysis of variance


Administrative Panel on Laboratory Animal Care


Arginase 1




Fetal bovine serum


Fluorescein isothiocyanate


Interferon gamma




Interleukin-1 receptor antagonist




Macrophage colony stimulation factor


Mesenchymal stem cell


Nuclear factor-κB




Prostaglandin E2


Roswell Park Memorial Institute


Reverse transcriptase-polymerase chain reaction


Tumor necrosis factor alpha


Alpha minimal essential medium


  1. 1.

    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.

  2. 2.

    Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747–54.

  3. 3.

    Loi F, Cordova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB. Inflammation, fracture and bone repair. Bone. 2016;86:119–30.

  4. 4.

    Einhorn TA, Gerstenfeld LC. Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015;11(1):45–54.

  5. 5.

    Alexander KA, Chang MK, Maylin ER, Kohler T, Muller R, Wu AC, Van Rooijen N, Sweet MJ, Hume DA, Raggatt LJ, et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. J Bone Miner Res. 2011;26(7):1517–32.

  6. 6.

    Lin TH, Tamaki Y, Pajarinen J, Waters HA, Woo DK, Yao Z, Goodman SB. Chronic inflammation in biomaterial-induced periprosthetic osteolysis: NF-kappaB as a therapeutic target. Acta Biomater. 2014;10(1):1–10.

  7. 7.

    Loi F, Cordova LA, Zhang R, Pajarinen J, Lin TH, Goodman SB, Yao Z. The effects of immunomodulation by macrophage subsets on osteogenesis in vitro. Stem Cell Res Ther. 2016;7(1):15.

  8. 8.

    Novack DV. Role of NF-kappaB in the skeleton. Cell Res. 2011;21(1):169–82.

  9. 9.

    Lin TH, Pajarinen J, Lu L, Nabeshima A, Cordova LA, Yao Z, Goodman SB. NF-kappaB as a therapeutic target in inflammatory-associated bone diseases. Adv Protein Chem Struct Biol. 2017;107:117–54.

  10. 10.

    Mountziaris PM, Tzouanas SN, Mikos AG. Dose effect of tumor necrosis factor-alpha on in vitro osteogenic differentiation of mesenchymal stem cells on biodegradable polymeric microfiber scaffolds. Biomaterials. 2010;31(7):1666–75.

  11. 11.

    Mountziaris PM, Dennis Lehman E, Mountziaris I, Sing DC, Kasper FK, Mikos AG. Effect of temporally patterned TNF-alpha delivery on in vitro osteogenic differentiation of mesenchymal stem cells cultured on biodegradable polymer scaffolds. J Biomater Sci Polym Ed. 2013;24(15):1794–813.

  12. 12.

    Cho HH, Shin KK, Kim YJ, Song JS, Kim JM, Bae YC, Kim CD, Jung JS. NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. J Cell Physiol. 2010;223(1):168–77.

  13. 13.

    Croes M, Oner FC, Kruyt MC, Blokhuis TJ, Bastian O, Dhert WJ, Alblas J. Proinflammatory mediators enhance the osteogenesis of human mesenchymal stem cells after lineage commitment. PLoS One. 2015;10(7):e0132781.

  14. 14.

    Lu Z, Wang G, Dunstan CR, Chen Y, Lu WY, Davies B, Zreiqat H. Activation and promotion of adipose stem cells by tumour necrosis factor-alpha preconditioning for bone regeneration. J Cell Physiol. 2013;228(8):1737–44.

  15. 15.

    Lu Z, Wang G, Dunstan CR, Zreiqat H. Short-term exposure to tumor necrosis factor-alpha enables human osteoblasts to direct adipose tissue-derived mesenchymal stem cells into osteogenic differentiation. Stem Cells Dev. 2012;21(13):2420–9.

  16. 16.

    Briolay A, Lencel P, Bessueille L, Caverzasio J, Buchet R, Magne D. Autocrine stimulation of osteoblast activity by Wnt5a in response to TNF-alpha in human mesenchymal stem cells. Biochem Biophys Res Commun. 2013;430(3):1072–7.

  17. 17.

    Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2(2):141–50.

  18. 18.

    Francois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20(1):187–95.

  19. 19.

    Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42–9.

  20. 20.

    Wang L, Zhao Y, Liu Y, Akiyama K, Chen C, Qu C, Jin Y, Shi S. IFN-gamma and TNF-alpha synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFkappaB signaling. Stem Cells. 2013;31(7):1383–95.

  21. 21.

    Lin TH, Sato T, Barcay KR, Waters H, Loi F, Zhang R, Pajarinen J, Egashira K, Yao Z, Goodman SB. NF-kappaB decoy oligodeoxynucleotide enhanced osteogenesis in mesenchymal stem cells exposed to polyethylene particle. Tissue Eng Part A. 2015;21(5-6):875–83.

  22. 22.

    Lin TH, Yao Z, Sato T, Keeney M, Li C, Pajarinen J, Yang F, Egashira K, Goodman SB. Suppression of wear-particle-induced pro-inflammatory cytokine and chemokine production in macrophages via NF-kappaB decoy oligodeoxynucleotide: a preliminary report. Acta Biomater. 2014;10(8):3747–55.

  23. 23.

    Rao AJ, Gibon E, Ma T, Yao Z, Smith RL, Goodman SB. Revision joint replacement, wear particles, and macrophage polarization. Acta Biomater. 2012;8(7):2815–23.

  24. 24.

    Nakao S, Ogtata Y, Shimizu E, Yamazaki M, Furuyama S, Sugiya H. Tumor necrosis factor alpha (TNF-alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Mol Cell Biochem. 2002;238(1–2):11–8.

  25. 25.

    Bouffi C, Bony C, Courties G, Jorgensen C, Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 2010;5(12):e14247.

  26. 26.

    Vasandan AB, Jahnavi S, Shashank C, Prasad P, Kumar A, Prasanna SJ. Human mesenchymal stem cells program macrophage plasticity by altering their metabolic status via a PGE2-dependent mechanism. Sci Rep. 2016;6:38308.

  27. 27.

    Guihard P, Danger Y, Brounais B, David E, Brion R, Delecrin J, Richards CD, Chevalier S, Redini F, Heymann D, et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells. 2012;30(4):762–72.

  28. 28.

    Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O’Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109(11):1405–15.

  29. 29.

    Carvalho JL, Braga VB, Melo MB, Campos AC, Oliveira MS, Gomes DA, Ferreira AJ, Santos RA, Goes AM. Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J Cell Mol Med. 2013;17(5):617–25.

  30. 30.

    de Oliveira LF, Almeida TR, Ribeiro Machado MP, Cuba MB, Alves AC, da Silva MV, Rodrigues Junior V, Dias da Silva VJ. Priming mesenchymal stem cells with endothelial growth medium boosts stem cell therapy for systemic arterial hypertension. Stem Cells Int. 2015;2015:685383.

  31. 31.

    Aktas E, Chamberlain CS, Saether EE, Duenwald-Kuehl SE, Kondratko-Mittnacht J, Stitgen M, Lee JS, Clements AE, Murphy WL, Vanderby R. Immune modulation with primed mesenchymal stem cells delivered via biodegradable scaffold to repair an Achilles tendon segmental defect. J Orthop Res. 2017;35(2):269–80.

  32. 32.

    Saether EE, Chamberlain CS, Aktas E, Leiferman EM, Brickson SL, Vanderby R. Primed mesenchymal stem cells alter and improve rat medial collateral ligament healing. Stem Cell Rev. 2016;12(1):42–53.

  33. 33.

    Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009;37(12):1445–53.

  34. 34.

    Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.

  35. 35.

    Sun Z, Wang S, Zhao RC. The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol. 2014;7:14.

  36. 36.

    Lu Z, Chen Y, Dunstan C, Roohani-Esfahani S, Zreiqat H. Priming adipose stem cells with tumor necrosis factor-alpha preconditioning potentiates their exosome efficacy for bone regeneration. Tissue Eng Part A. 2017;23(21–22):1212–20.

  37. 37.

    Na YR, Yoon YN, Son DI, Seok SH. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS One. 2013;8(5):e63451.

  38. 38.

    Luan B, Yoon YS, Le Lay J, Kaestner KH, Hedrick S, Montminy M. CREB pathway links PGE2 signaling with macrophage polarization. Proc Natl Acad Sci U S A. 2015;112(51):15642–7.

  39. 39.

    Rong Y, Yuan CH, Qu Z, Zhou H, Guan Q, Yang N, Leng XH, Bu L, Wu K, Wang FB. Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. Sci Rep. 2016;6:23824.

  40. 40.

    Lee MJ, Kim J, Kim MY, Bae YS, Ryu SH, Lee TG, Kim JH. Proteomic analysis of tumor necrosis factor-alpha-induced secretome of human adipose tissue-derived mesenchymal stem cells. J Proteome Res. 2010;9(4):1754–62.

  41. 41.

    Xie C, Ming X, Wang Q, Schwarz EM, Guldberg RE, O’Keefe RJ, Zhang X. COX-2 from the injury milieu is critical for the initiation of periosteal progenitor cell mediated bone healing. Bone. 2008;43(6):1075–83.

  42. 42.

    Xie C, Liang B, Xue M, Lin AS, Loiselle A, Schwarz EM, Guldberg RE, O’Keefe RJ, Zhang X. Rescue of impaired fracture healing in COX-2-/- mice via activation of prostaglandin E2 receptor subtype 4. Am J Pathol. 2009;175(2):772–85.

  43. 43.

    Altman RD, Latta LL, Keer R, Renfree K, Hornicek FJ, Banovac K. Effect of nonsteroidal antiinflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma. 1995;9(5):392–400.

  44. 44.

    Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B, Cullinane D, Einhorn TA. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res. 2003;21(4):670–5.

  45. 45.

    Goodman S, Ma T, Trindade M, Ikenoue T, Matsuura I, Wong N, Fox N, Genovese M, Regula D, Smith RL. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res. 2002;20(6):1164–9.

  46. 46.

    Pountos I, Georgouli T, Calori GM, Giannoudis PV. Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. Sci World J. 2012;2012:606404.

  47. 47.

    Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine (Phila Pa 1976). 1998;23(7):834–8.

  48. 48.

    Long J, Lewis S, Kuklo T, Zhu Y, Riew KD. The effect of cyclooxygenase-2 inhibitors on spinal fusion. J Bone Joint Surg Am. 2002;84-A(10):1763–8.

  49. 49.

    Yoon DS, Yoo JH, Kim YH, Paik S, Han CD, Lee JW. The effects of COX-2 inhibitor during osteogenic differentiation of bone marrow-derived human mesenchymal stem cells. Stem Cells Dev. 2010;19(10):1523–33.

  50. 50.

    Lu LY, Loi F, Nathan K, Lin T-H, Pajarinen J, Gibon E, Nabeshima A, Cordova LA, Jamsen E, Yao Z, et al. Pro-inflammatory M1 macrophages promote osteogenesis by mesenchymal stem cells via the COX-2-Prostaglandin E2 pathway. J Orthop Res. 2017;35(11):2378–85.

  51. 51.

    Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One. 2010;5(4):e10088.

  52. 52.

    Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I, Costa H, Canones C, Raiden S, Vermeulen M, et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One. 2010;5(2):e9252.

Download references


Not applicable.


This work was supported by NIH grants (2R01AR055650, 1R01AR063717) and the Ellenburg Chair in Surgery at Stanford University. JP was supported by a grant from the Jane and Aatos Erkko foundation.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author information

TL performed the experiments and wrote the manuscript supervised by SBG. JP, EJ, and SBG edited the manuscript. AN, LL, KN, and ZY performed the cell primary cell preparation, data interpretation, and manuscriptediting. All authors read and approved the final manuscript.

Correspondence to Stuart B. Goodman.

Ethics declarations

Ethics approval

Stanford’s Administrative Panel on Laboratory Animal Care (APLAC) approved the animal cell isolation protocol (APLAC 17566).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1: Figure S1.

Showing immunophenotypes of murine bone marrow-derived MSCs. Surface marker expression in murine MSCs at passage 4 analyzed by flow cytometry. Figure S2. showing titration of LPS dose for MSC preconditioning with TNF-α to modulate murine macrophage polarization. Murine MSCs were preconditioned with TNF-α (20 ng/ml) plus LPS (1–20 μg/ml) for 3 days, and cocultured with M1 macrophages for 24 hours. M2 (Arg1 and CD206) and M1 (TNF-α/IL-1Ra) macrophage marker expression in macrophages measured by quantitative PCR. Data presented as fold-change compared to macrophages cocultured with unstimulated control MSCs. *p < 0.05, **p < 0.01, ***p < 0.005. Figure S3. showing increased osteogenic differentiation in the MSCs with temporal inhibition of COX2 signaling. MSCs were treated with 25 μM Celecoxib in osteogenic media at indicated time points. Osteogenic differentiation ability examined by bone mineralization (Alizarin Red staining) at week 3. *p < 0.05, ***p < 0.005. Figure S4. showing increased iNOS expression in MSCs preconditioned with TNF-α and/or LPS. Murine MSCs were preconditioned with TNF-α (20 ng/ml) plus LPS (1–20 μg/ml) for 3 days, and washed out for 24 hours. Expression of iNOS determined by quantitative PCR. Data presented as fold-change compared to macrophages cocultured with unstimulated control MSCs. ***p < 0.005. (PDF 3973 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lin, T., Pajarinen, J., Nabeshima, A. et al. Preconditioning of murine mesenchymal stem cells synergistically enhanced immunomodulation and osteogenesis. Stem Cell Res Ther 8, 277 (2017) doi:10.1186/s13287-017-0730-z

Download citation


  • Mesenchymal stem cells
  • Immunomodulation
  • Macrophage polarization
  • Osteogenesis
  • Prostaglandin E2